Compare iShares 10 20 Year Treasury Bond ETF (TLH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 10 20 Year Treasury Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? iShares 10 20 Year Treasury Bond ETF trades at $96.56, while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| TLH | XBI | |
|---|---|---|
Sector | Fixed Income | Broad Market / Factor |
52-Week High | $105.36 | $164.28 |
52-Week Low | $96.39 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TLH trades at $96.57, up 0.19% today, with a bearish technical signal from moving averages and neutral oscillators. Recent dividends include $0.38 (July 2026), $0.36 (June 2026), and $0.41 (May 2026). Key financial ratios like P/E and ROE are unavailable, limiting fundamental clarity. Support and resistance cluster near $96-$97, indicating tight price consolidation amid weak momentum.
The outlook is cautious due to missing financial metrics and bearish technicals. Risks include reliance on dividend stability and macroeconomic pressures from rising yields. Opportunities may arise if fundamentals improve, but current data suggests limited upside without clearer earnings visibility or positive analyst sentiment.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
